OBJECTIVES: Multimodal management of N2 non-small-cell lung cancer is still a matter of debate. In particular, the place of surgery for persistent N2 after induction treatment is controversial and surgery is usually reserved for patients experiencing a mediastinal downstaging ( pN1 and pN0). We aimed to evaluate whether there might exist subgroups of pN2 according to the lymph node ratio (LNR).
INTRODUCTION
Non-small-cell lung cancer (NSCLC) remains the first cause of cancer-related deaths in the world [1] . Nearly 30% of newly diagnosed NSCLC have locally advanced disease staged as IIIA and IIIB [2] , and 10% in the group are classified as N2 because of the presence of homolateral mediastinal lymph node involvement [2] . The best treatment option for these patients is still a matter of debate. Indeed, some phase II and III trials and retrospective series have shown an improved overall survival (OS) for N2 NSCLC treated by induction treatment followed by surgery [3] [4] [5] [6] . On the other hand, according to some authors, patients with preoperative N2 disease are not good candidates for surgery because of poor outcomes, with a 5-year OS only reaching 10% [7] . Surgery is usually reserved for N1 or N0 patients experiencing a mediastinal downstaging after induction therapy [8] . However, clinical mediastinal restaging may be inaccurate, and there are no sufficient data in the literature to conclude which groups of patients with persistent N2 disease may benefit from surgery. Otherwise, in resected NSCLC, like in other cancers, several reports have recently presented out data on the prognostic value of the lymph node ratio (LNR), defined as the number of lymph nodes (LNs) involved divided by the number of LNs examined), with poorer outcomes in case of a high LNR [9] [10] [11] [12] .
Our study was aimed at identifying the prognostic factors of surgical-combined modality with resectable patients with persistent N+ disease after induction treatment. In addition, its findings drew attention on the essential role of the LNR compared with mediastinal downstaging.
MATERIALS AND METHODS
The study was approved by our institutional review board. We retrospectively analysed the data of 152 patients who underwent, between January 1996 and January 2012, an induction treatment before surgery for cN2 NSCLC. Multimodality treatment, including surgery, was decided during the multidisciplinary board (MDB) in the presence of a certified thoracic surgeon. As a routine in our centre, a perioperative treatment was systematically decided regardless of the postoperative pathological Tumor Node Metastassis (pTNM) stage. Neoadjuvant treatment consisted of chemotherapy alone, or in combination with radiation therapy. All chemotherapy regimens were platinum-based. Because some patients were referred to us by physicians from different centres, no uniform protocol of neoadjuvant chemo-radiotherapy was used. A preoperative evaluation was conducted to assess the resectability and the absence of distant metastases. It comprised a contrast-enhanced computed tomography (CT) scan of the thorax and the upper abdomen and it was combined with a contrast-enhanced CT scan of the brain and, in more recent years, an fluorodeoxyglucosepositron emission tomography (FDG-PET) whole-body scan. In case of suspicion of persistent N2, histopathological confirmation was obtained by mediastinoscopy. In more recent years, endobronchial ultrasound (EBUS) cytopuncture was first performed in case of positive PET. Mediastinoscopy was then performed in case of negativity of EBUS. However, the decision of surgery was based only on CT for 35 patients (23%). Finally, only patients preoperatively staged without N2 involvement, and with objective response or stable disease according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria [13] were deemed suitable for surgery. The whole group underwent a curative surgery at the Department of Thoracic Surgery of Strasbourg University Hospital (France). In accordance with the recommendations of the French Society of Thoracic and Cardio-vascular Surgeons [14] , appropriate anatomical resections (lobectomies, bi-lobectomies or pneumonectomies), as well as systematic radical mediastinal lymphadenectomy consisting of the ablation of the stations 2R, 34, 4R, 7, 8 and 9 on the right side, and stations 4L, 5, 6, 7, 8 and 9 on the left side were performed, regardless of the preoperative thoracic imaging. During the study period, the video-assisted thoracic surgery programme had not begun in our centre. For this reason, all lung resections were performed by thoracotomy.
The absence of disease in the lung and the nodes was considered as a complete histological response. Mediastinal downstaging was defined by the absence of gross and microscopic disease in the resected mediastinal nodes (i.e. pN0 and pN1).
Adjuvant treatment, consisting of chemotherapy, radiation therapy (RT) alone or combined with chemo-radiotherapy, was decided at the MDB. Adjuvant chemotherapy consisted of platinum-based treatment, whereas RT was performed after CT based three-dimensional treatment planning with a linear accelerator. The target volume included the area of loco-regional LN, plus a margin of 2 cm. The dose per fraction was 2 Gray (Gy), given once daily, 5 days per week, up to a total dose of 60 Gy for R0 patients without extracapsular spread (ECS) or 66 Gy in case of incomplete resection and/or ECS.
Charlson comorbidity index (CCI) was calculated for each patient. The CCI incorporates 19 chronic diseases weighted according to association with mortality. We grouped patients according to the total score into the following established categories: 0 (no comorbidity); 1-2 (average); 3-4 (moderate) and ≥5 (severe). Skip metastases were defined as N2 involvement without N1. Otherwise, microscopic nodal metastases were considered for metastases between 0.2 and 2 mm.
Statistical analysis was performed using IBM SPSS v.20. Comparisons between groups were performed using χ 2 , Fisher's or Student's t-tests. OS was calculated from the first time of diagnosis of NSCLC until death or the last follow-up. The prognostic influence of variables on survival was assessed using log-rank tests and Cox proportional hazard models. All tests were two-sided and the variables were considered significant for P-values inferior to 0.05. All variables with a P-value inferior to 0.2 were tested in multivariate analysis.
RESULTS
The demographic data of the cohort are sampled in Table 1 . Our population was composed of 121 (79.6%) males and 31 (20.4%) However, the number of LNs removed was not a good predictor of the LNR. Indeed, the correlation between the two variables was R = 0.245, whereas the R 2 value was 0.06 (P = 0.23). Complete histological response was observed in 5 patients (3.3%), whereas a mediastinal downstaging was noted for 92 patients (60.5%).
In univariate analysis (Table 2) , the OS was influenced by the type of resection without reaching significance: (30 ± 3.43 months for lobectomy vs 40 ± 2.69 months for bi-lobectomy and 32 ± 9.39 months for pneumonectomy, P = 0.07). Concerning OS, there was no significant difference between pooled bilobectomies/lobectomies and pneumonectomy (32 ± 5.57 months vs 32 ± 9.39 months, P = 0.68). OS proved better in case of right pneumonectomy (59 ± 14.04 months), while it was 27 ± 8.74 months for left pneumonectomy (P = 0.86). Moreover, the higher the pT after surgery, the shorter was the median OS (P = 0.06). OS was significantly influenced by ECS. Indeed, it reached 32 months in the absence of ECS, whereas it was only 24 months in the case of ECS (P = 0.01). OS was significantly modified according to the pN after surgery (Fig. 1) . Indeed, it was 65 ± 2.45 months for pN0 patients, worsening among pN1 patients (44 ± 2.14 months) and it only reached 19 ± 1.72 months for pN2 patients (P <0.0001). Furthermore, patients with an LNR superior to 1/3 had a significantly poorer OS (30 ± 3.77 months vs 16 ± 1.39 months, P <0.0001) (Fig. 2) . In addition, when pN1 and pN2 patients were staged according to the LNR, the OS was significantly influenced. Indeed, it was divided by two for pN1 patients with an LNR ≥ 1/3 Bold values were used to highlight significant P-values. N+ were defined as patients with lymph node involvement regardless of the hilar or mediastinal location. (48 ± 2.64 months vs 26 ± 5.65 months, P <0.001) (Fig. 3A) , whereas it decreased from 26 ± 0.87 to 15 ± 1.85 months (P <0.0001) for pN2 patients (Fig. 3B) . The type of adjuvant treatment also had a significant influence on OS. Indeed, it was significantly better with radiochemotherapy than with chemotherapy or RT alone (P <0.0001). However, there was no difference of adjuvant treatment regarding the LNR (P = 0.76). Moreover, the CCI significantly influenced the median OS (P <0.0001). Finally, OS was influenced neither by neoadjuvant treatment, histology, number of N2 stations involved, microscopic nodal metastases nor gender.
In multivariate analysis ( 
DISCUSSION
The optimal treatment for N2 NSCLC is still debated. It is now widely accepted that surgery alone leads to a poorly complete resectability rate with a 5-year OS rate inferior to 10% [15] and that a possible approach for N2 patients might be a multimodality treatment [8, [16] [17] [18] . However, patients who may benefit from surgery are not clearly identified. Indeed, in the North American Intergroup 0139 trial [19] , potentially resectable patients, with pathology-proven N2, were randomized into definitive radiochemotherapy versus radio-chemotherapy followed by surgery. The authors found a better 5-year OS in the multimodal surgical group (27 vs 20%) without a significant difference, which was attributed to high hospital mortality rate after pneumonectomy, reaching 26% in the surgical arm. On the contrary, the EORTC trial 08941 [20] found no difference on survival between surgery and RT following induction chemotherapy. However, only patients with unresectable disease whose benefit from surgery may be uncertain were enrolled, and resection was incomplete for 50% of patients in the surgical arm leading to a poor 5-year OS, inferior to 15%.
Mediastinal downstaging is the best studied prognostic factor. The 5-year OS published for patients with persistent N2 disease after induction treatment is inferior to 20%, whereas it can reach 40% for pN0 patients [8] . Our results are very similar to the literature data. Indeed, the median OS reached 65 months for pN0 patients and 44 months for pN1, decreasing to 19 months for pN2 patients. The corresponding 5-year OS rates were 57.2, 31.8 and 0%, respectively. This observation was confirmed in multivariate analysis [HR: 0.184 (95% CI: 0.084-0.403), P <0.0001]. Even if we did not observe a significant difference concerning the N2 level, 
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S. Renaud et al. / Interactive CardioVascular and Thoracic Surgerythe median OS reached 36 months in single N2 level, whereas it decreased to 26 months in case of involvement of 3 levels. The smaller OS for persistent N2 in our cohort compared with the published data may be partially explained by the different regimens of adjuvant treatment. Indeed, we noted that OS was significantly influenced by the type of adjuvant treatment, with a poorer median OS for RT alone, exclusively offered to pN2 patients. Consequently, we cannot conclude that persistent N2 should be excluded from surgery in our cohort, since they did not benefit from a maximalist treatment, and one can wonder whether survival could have been better in case of adjuvant radio-chemotherapy instead of RT alone. However, our study covers a 16-year period during which there was an evolution in the radiation therapy techniques. Consequently, no strict conclusion concerning the beneficial management of different adjuvant treatments can be drawn from this observation. Nevertheless, the latest recommendations of the American College of Chest Physicians recommend the use of adjuvant chemotherapy for pN2 R0 patients and limit the use of RT in case of a higher risk of loco-regional recurrence [21] .
Otherwise, the LNR has recently emerged as a prognostic factor in NSCLC [9] [10] [11] [12] . Complete mediastinal lymphadenectomy has become a gold standard in oncological surgery, allowing a more accurate staging and leading to more adapted adjuvant treatments. However, the nodal classification of the seventh TNM edition is based on the idea that LN metastasis occurs in LNs neighbouring the primary tumour, and then sequentially spreads to the other nodes. Nevertheless, recent studies on skip metastasis have revealed that metastasis can initially occur in the mediastinum [22] . Some authors have thereby argued that the number of metastastic LNs might be a better prognostic factor [23] . However, the number of LNs might be influenced by the technique of dissection (i.e. sampling versus complete lymphadenectomy), histopathological count, induction treatment and/or risk of fragmentation. This seems to be thwarted by the LNR. Indeed, as supported by our linear regression model, the LNR seems to be independent of the number of LNs removed. Furthermore, the LNR seems to be more robust against fragmentation, because if nodes are fragmented, both the risk of fragmentation of metastatic LNs and the total number of LNs will increase. In paired univariate and multivariate analysis, we observed that OS was significantly influenced by the LNR [HR: 0.359 (95% CI: 0.194-0.665), P = 0.001]. We also noted that an LNR of 1/3 was a cut-off and that the median OS was significantly lower in case of higher LNR for each lymph node level (48 vs 26 months, P <0.0001). It is interesting to note that when patients with pN1 and pN2 patients were stratified according to the LNR status, the median OS of pN1 patients with an LNR ≥ 1/3 was not significantly different from pN2 patients with a small LNR ( 26 months for both groups). This observation pleads for a classification of both N2 and N1 patients into different subgroups according to the LNR. In particular, pN1 patients with a high LNR had an as bad median OS as pN2 patients with a low LNR, with no 5-year OS. Nevertheless, it seems unreasonable to exclude pN1 patients from surgery for whom long-term survival can be achieved. On the other hand, one can wonder whether the subgroup of pN1 patients with high LNR are really good candidates for surgery. However, preoperative evaluation of N1 status and LNR have so far been difficult. Indeed, remediastinoscopy after induction treatment does not enable one to establish an accurate LNR. Moreover, sensitivity of routinely performed thoracic imaging does not seem to be sufficient to preoperatively evaluate the LNR. In particular, the sensitivity of PET to detect lymph nodes metastasis only reaches 74%, and is less sensitive for lymph nodes of small size [24] . This might be a problem in LNR evaluation since 20% of nodes <1 cm are proven tumoural at histological examination [24] . Consequently, it seems that, in case of stable or partial response, persistent N+ patients after induction treatment should not be excluded from surgery and that different subgroups of patients according to the LNR might benefit from different adjuvant treatments. In particular, according to the work of Urban et al. [12] , the postoperative use of RT in patients with a high LNR may lead to longer OS. However, the LNR cut-off varies in different studies. Matsuguma et al. [25] reported a worse OS in case of an LNR > 12%; Jonnalagadda et al. [9] divided their population into three groups (<15%, between 16 and 50%, and >50%) and observed a worsening OS as the LNR increased, like Nwogu et al. [10] , who divided their population into <24%, between 25 and 49%, and >50%. As the LNR is clearly emerging as an important prognostic factor in NSCLC, prospective studies on larger cohorts are therefore necessary to define a validated cut-off.
Not surprisingly and like other previous publications, we observed that pT stage after surgery and R1 resection (here patients with ECS) had a significant impact on OS, even if it was not confirmed in multivariate analysis [8, 16] .
Some authors advocate that right-sided pneumonectomy should not be performed after induction treatment because of a worse OS and mortality [18, 19] . We observed a better OS for bilobectomies when compared with other types of resection, but not when pooled bilobectomies and lobectomies were compared with pneumonectomy. A better OS for bilobectomy might be explained by the fact that patients in this group harboured significantly lower LNRs than other patients (data not shown). Otherwise, the median OS for pneumonectomy in our cohort is totally acceptable and similar to the data in the literature [16] . Like other authors and because of this observation, we therefore come to the conclusion that pneumonectomy is not a contraindication to surgery.
However, our study suffers from a few limitations that must be taken into account when the results are interpreted. First, it is a retrospective study based on a 16-year period during which there might have been modifications concerning patients' management, in particular in terms of the RT and chemotherapy regimen. Moreover, different neoadjuvant regimens and the absence of protocol for adjuvant treatment could have been responsible for another bias. Finally, histopathological proof of persistent N2 was not obtained for 23% of the patients. However, mediastinoscopy has led to an accurate staging in 92 patients, corresponding to a sensitivity of 78%, totally in accordance with the literature findings. Indeed, only persistent pN2 were not correctly preoperatively staged by invasive staging, and patients for whom a pathological proof was not obtained were all finally pN2.
In conclusion, to the best of our knowledge, our study is the first one to consider the LNR and mediastinal downstaging as prognostic factors in persistent N+ after induction treatment. Our observation supports the idea that mediastinal downstaging is not a sufficient prognostic factor, as pN1 patients with a high LNR had the same OS as pN2 patients with a low LNR. However, long-term survival can be achieved for low LNR pN1 patients. Because routinely used preoperative thoracic imaging does not allow one to accurately evaluate the LNR, N1 patients should not be excluded from surgery. Postoperative LNR may thus help to decide which adjuvant treatment to perform, with more aggressive treatments for higher LNRs. In particular, adjuvant RT, probably combined with chemotherapy, may be helpful in patients with high LNRs, as previously reported by Urban et al. [12] . However, our study suffers from the limitations listed above; consequently prospective studies are necessary to confirm these data.
Conflict of interest: none declared.
